Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 1997

View Archived Issues

UCSF receives NIH funding for research into anticancer protease inhibitors

Genentech granted U.S. patents for factor VIII

Selective 5-HT1Dalpha receptor agonists from MS&D

Astra prepares NOS inhibitors

Antiviral dihydropyrans from Biota

Synthelabo prepares serotonergic agents

Arzneimittelwerk describes novel antiepileptic agents

Synthelabo reports agents for urinary incontinence

First launch for new indication of cabergoline

Aldara approved in U.S.

MDR-reversing agents described by Nikken Chemicals

Fujsawa selects adenosine A1 receptor antagonist for development

Fujisawa describes new oral cephem antibiotic

Eisai prepares potent antitumor agents

TX-1877: new hypoxic cell radiation enhancer

Lilly granted rights to gene/protein involved in islet neogenesis

RPR cleared to market Taxotere in Malaysia and Hungary

Encouraging phase III results reported for lamivudine as hepatitis B treatment

Wyeth-Ayerst and Elan develop new formulation of Lodine

Milestone reached in Genome Therapeutics/Astra H. pylori collaboration

Progress in Cubist/Bristol-Myers Squibb antiinfective collaboration

Treatment for rhinitis undergoes further development in Australia

Hybridon selects HPV drug candidate

Encouraging results from preclinical trial of Atlantic's RSV therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...